SCHEMBL2523503

SCHEMBL2523503

CC(C)(C)C1N(C(=O)O)CCCN(C(=O)O)CCN(Cc2ccc(O)c3ncccc23)CCCN(C(=O)O)C1(C(C)(C)C)C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.50
MAPT P10636 5/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
ALDH1A1 P00352 3/20 0.50
KMT2A Q03164 3/20 0.50
MPI P34949 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
TP53 P04637 3/20 0.48
NFKB1 P19838 3/20 0.48
NFKB2 Q00653 3/20 0.48
RELA Q04206 3/20 0.48
ALOX12 P18054 2/20 0.48
BRD4 O60885 2/20 0.48
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
APP P05067 11/20 0.48
USP2 O75604 1/20 0.46
ALOX15 P16050 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2525120 0.98 KDM4E (0.50) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL2523696 0.90 MAPT (0.46) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL2521712 0.84 KDM4E (0.55) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL2521716 0.82 KDM4E (0.53) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL2523506 0.79 KDM4E (0.51) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL2525125 0.78 KDM4E (0.50) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL2518215 0.74 MAPT (0.71) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL2521161 0.74 MAPT (0.71) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL2518129 0.73 MAPT (0.69) KDM4EMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL5594566 0.73 KDM4E (0.89) KDM4EMAPTL3MBTL1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139860-A2 DERIVATIVES OF THE AMINATED HYDROXYQUINOLINE CLASS FOR TREATING CANCERS Biopharmed Société à Responsabilité Limitée (FR) 2010-01-06 EP claimed
WO-2008135671-A2 DERIVATIVES OF THE AMINATED HYDROXYQUINOLINE CLASS FOR TREATING CANCERS BIOPHARMED Société à responsabilité limitée (FR) 2008-11-13 WO claimed
US-20110251238-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE BIOPHARMED (FR) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251238-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE PPARA, PPARG, PPARD KDM4E 4239/4885MAPT 4323/4885L3MBTL1 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.